Drug profile · INN
oritavancin diphosphate
ORBACTIV
oritavancin diphosphate (ORBACTIV) is a peptidoglycan inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — oritavancin diphosphate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
oritavancin diphosphate (ORBACTIV) is a peptidoglycan inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Peptidoglycan inhibitor
Primary target: Peptidoglycan
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is oritavancin diphosphate?
oritavancin diphosphate (ORBACTIV) is a peptidoglycan inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for oritavancin diphosphate?
ORBACTIV is a marketed brand name for oritavancin diphosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oritavancin diphosphate?
oritavancin diphosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.